Impella Protected Percutaneous Coronary Intervention Outcomes Compared With Intra-aortic Balloon Pump: A Contemporary...

Area of Science:

• Cardiovascular Medicine
• Interventional Cardiology
• Biostatistics

Background:

• Traditional cardiovascular trial composite endpoints can obscure individual event importance.
• The Win Ratio (WR) is a modern statistical method addressing composite endpoint limitations.
• High-risk percutaneous coronary intervention (HRPCI) outcomes require nuanced evaluation.

Purpose of the Study:

• To compare the efficacy of Impella® versus intra-aortic balloon pump (IABP) in HRPCI using the Win Ratio.
• To pool data from the PROTECT-II and PROTECT-III studies for a comprehensive analysis.
• To evaluate major adverse cardiac and cerebrovascular events (MACCE) with a hierarchical endpoint structure.

Main Methods:

• Pooled data from PROTECT-II RCT and PROTECT-III study patients meeting PROTECT-II criteria.
• Win Ratio analysis based on a 90-day hierarchy: Mortality, Stroke, Spontaneous MI, Re-Hospitalization, Peri-Procedural MI.
• Win statistics (WR, Net Benefit, Win Odds) calculated, including sub-analyses for complex cases and study cohorts.

Main Results:

• The primary analysis (719 Impella, 211 IABP) showed a WR of 1.691 favoring Impella (p<0.001).
• Significant Net Benefit (0.166, p<0.001) and Win Odds (1.398, p<0.001) also favored Impella.
• Sub-analyses, including complex PCI cases, consistently demonstrated Impella's benefit.

Conclusions:

• Pooled Win Ratio analysis confirms superior 90-day outcomes for Impella® compared to IABP in HRPCI.
• The Win Ratio provides a more clinically relevant assessment of device efficacy in complex cardiovascular interventions.
• Findings support Impella® as a preferred mechanical circulatory support device in high-risk PCI scenarios.